Business Context and Reporting Period
Company: TECHNE Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2003
Business Overview: TECHNE is a holding company with two primary operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in Minneapolis, MN, and R&D Systems Europe Ltd. in Abingdon, England. The company operates through three segments: the Hematology Division (blood analysis controls), the Biotechnology Division (cytokines, antibodies, and assay kits for research), and R&D Europe (distribution of biotechnology products in Europe). The company also holds equity interests in ChemoCentryx, Inc. (26%) and Discovery Genomics, Inc. (39%).
Key Financial Metrics
| Metric | Fiscal 2003 | Fiscal 2002 | Fiscal 2001 |
|---|---|---|---|
| Net Sales | $145,011,000 | $130,900,000 | $115,357,000 |
| Gross Margin | 75.6% | 75.2% | 75.4% |
| Net Earnings | $45,396,000 | $27,130,000 | $34,045,000 |
| Diluted EPS | $1.08 | $0.64 | $0.80 |
| Operating Cash Flow | $54,089,000 | $27,667,000 | $46,372,000 |
| Cash & Equivalents | $117,501,000 | $97,064,000 | $97,072,000 |
| Long-Term Debt | $15,852,000 | $17,101,000 | $18,050,000 |
| Working Capital | $138,707,000 | $114,448,000 | $108,300,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% to $145.0 million, driven by a 22% increase in R&D Europe sales (partially due to favorable currency exchange rates) and a 7% increase in both the Biotechnology and Hematology divisions.
- Profitability Surge: Net earnings increased 67% to $45.4 million. This significant jump is primarily attributable to the absence of a $17.5 million litigation settlement charge recorded in fiscal 2002 and the cessation of goodwill amortization following the adoption of SFAS No. 142.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased 2% due to a $1.2 million reduction in profit sharing and stock bonus contributions. Research and development (R&D) expenses increased 18% to $20.6 million, largely due to increased losses from equity method investees (ChemoCentryx and Discovery Genomics).
- Cash Position: Cash and cash equivalents increased by $20.4 million, supported by strong operating cash flow of $54.1 million.
Guidance, Outlook, and Risks
- Outlook: Management expects income tax rates for fiscal 2004 to range from 35% to 36%. The company plans to finance future capital expenditures (estimated at $1.5 million for equipment and $8.6 million for construction) through existing cash and operating cash flow.
- Capital Projects: Significant construction is underway on a new facility in Minneapolis (completion planned for fiscal 2004) and a goat housing facility in southeast Minnesota for antibody production.
- Risks and Contingencies:
- Patent Litigation: The company initiated an interference proceeding with Streck Laboratories regarding patents for reticulocytes in hematology controls.
- Equity Investments: The company absorbs losses from ChemoCentryx and Discovery Genomics, which are included in R&D expenses. These losses increased in fiscal 2003.
- Foreign Currency: Approximately 25% of sales are in foreign currencies (primarily British Pound and Euro), exposing the company to exchange rate fluctuations.
- Regulatory: Hematology controls and certain diagnostic kits are subject to FDA regulation. Delays in approvals could impact new product launches.
Investor Verification Checklist
- Exclusion of One-Time Charges: Verify that the comparison of fiscal 2003 earnings to fiscal 2002 accounts for the $17.5 million litigation settlement charge that depressed 2002 results.
- Accounting Change Impact: Confirm the impact of SFAS No. 142 (Goodwill and Other Intangible Assets) on reported earnings, as goodwill amortization ceased in fiscal 2003.
- Equity Method Losses: Review the specific losses attributed to ChemoCentryx ($2.6 million) and Discovery Genomics ($0.6 million) included in R&D expenses.
- Currency Sensitivity: Assess the impact of the strengthening British Pound on R&D Europe's reported revenue growth versus organic growth.
- Capital Expenditure Commitments: Verify the remaining construction costs for the Minneapolis facility expansion (estimated at $7 million) and the new Minnesota property ($1.6 million).